Howe & Rusling’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-100
Closed -$19K 1011
2021
Q1
$19K Sell
100
-50
-33% -$10.3K ﹤0.01% 413
2020
Q4
$29K Buy
150
+85
+131% +$15.5K ﹤0.01% 339
2020
Q3
$10K Hold
65
﹤0.01% 449
2020
Q2
$8K Buy
65
+28
+76% +$3.29K ﹤0.01% 463
2020
Q1
$4K Buy
+37
New +$3.57K ﹤0.01% 538

Other funds holding RGEN

Howe & Rusling's RGEN Position: Q2 2021 in Review

Howe & Rusling sold out of Repligen (RGEN) in Q2 2021, closing a stake of 100 shares — an estimated $19K sold.

Howe & Rusling first reported a position in RGEN in Q1 2020 and held it in 5 quarters. The position peaked at $29K in Q4 2020. 429 funds tracked by Wall St. Rank hold RGEN as of Q2 2021.

  • Howe & Rusling reported no remaining Repligen position as of Q2 2021 after selling out during the quarter.
  • Howe & Rusling sold 100 Repligen shares in Q2 2021, an estimated $19K.
  • Howe & Rusling first reported a position in Repligen in Q1 2020 and held it in 5 quarters.
  • Howe & Rusling's Repligen position peaked at $29K in Q4 2020.
  • 429 funds tracked by Wall St. Rank held Repligen as of Q2 2021.

Based on Howe & Rusling's 13F filing for Q2 2021, filed 13 Aug 2021.